S 3741119th CongressIn Committee

Biosecurity Modernization and Innovation Act of 2026

Standard Summary
Balanced plain-English summary

This Senate bill would require the Commerce Department to regulate providers of synthetic nucleic acids and nucleic acid synthesizing equipment. It mandates screening of orders and customers, a list of sequences of concern, conformity assessments, NIST technical support, a biotechnology governance sandbox, and a federal biosecurity oversight assessment and implementation plan.

Key Points

  • 1Requires covered synthetic nucleic acid providers to screen orders for sequences of concern and verify customer identity and legitimacy.
  • 2Directs Commerce to establish and regularly update a sequences-of-concern list, operate a conformity assessment and auditing system, and allow civil penalties for violations.
  • 3Tasks NIST with developing standards, testing, and evaluation for screening protocols and sequence-to-function models.
  • 4Creates a biotechnology governance sandbox and requires an interagency assessment and implementation plan to streamline federal biosecurity and biosafety oversight.
  • 5Requires annual reports to Congress and provides confidentiality protections for customer information submitted during screening.

Impact Areas

Synthetic nucleic acid providersNucleic acid synthesizing equipment manufacturers and resellersBiotechnology and research institutionsCommerce Department and NISTNational security and public health agencies
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026